Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1989 Aug;48(8):662–666. doi: 10.1136/ard.48.8.662

Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

V Kyle 1, B L Hazleman 1
PMCID: PMC1003843  PMID: 2782976

Abstract

In a prospective study of 74 patients and a retrospective study of 35 patients with polymyalgia rheumatica/giant cell arteritis steroid related side effects occurred in at least one third of patients, and in two thirds if weight gain was included. Side effects were significantly related to an initial prednisolone dose of more than 30 mg and to the cumulative prednisolone dose. Patients taking a mean daily dose of 5 mg prednisolone or less were significantly less likely to develop side effects.

Full text

PDF
666

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayoub W. T., Franklin C. M., Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med. 1985 Sep;79(3):309–315. doi: 10.1016/0002-9343(85)90309-2. [DOI] [PubMed] [Google Scholar]
  2. BOURA A. L., COPP F. C., GREEN A. F. Amidines as adrenergic neurone blocking agents. Nature. 1962 Sep 22;195:1213–1214. doi: 10.1038/1951213a0. [DOI] [PubMed] [Google Scholar]
  3. Becker B., Podos S. M., Asseff C. F., Cooper D. G. Plasma cortisol suppression in glaucoma. Am J Ophthalmol. 1973 Jan;75(1):73–76. doi: 10.1016/0002-9394(73)90654-5. [DOI] [PubMed] [Google Scholar]
  4. Becker B., Shin D. H., Palmberg P. F., Waltman S. R. HLA antigens and corticosteroid response. Science. 1976 Dec 24;194(4272):1427–1428. doi: 10.1126/science.1006308. [DOI] [PubMed] [Google Scholar]
  5. Behn A. R., Perera T., Myles A. B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis. 1983 Aug;42(4):374–378. doi: 10.1136/ard.42.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bengtsson B. A., Malmvall B. E. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand. 1981;209(5):337–345. doi: 10.1111/j.0954-6820.1981.tb11604.x. [DOI] [PubMed] [Google Scholar]
  7. Bigger J. F., Palmberg P. F., Becker B. Increased cellular sensitivity to glucocorticoids in primary open-angle glaucoma. Invest Ophthalmol. 1972 Oct;11(10):832–837. [PubMed] [Google Scholar]
  8. Conn H. O., Blitzer B. L. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med. 1976 Feb 26;294(9):473–479. doi: 10.1056/NEJM197602262940905. [DOI] [PubMed] [Google Scholar]
  9. David D. S., Grieco M. H., Cushman P., Jr Adrenal glucocorticoids after twenty years. A review of their clinically relevant consequences. J Chronic Dis. 1970 Mar;22(10):637–711. doi: 10.1016/0021-9681(70)90078-0. [DOI] [PubMed] [Google Scholar]
  10. Fainaru M., Friedman G., Friedman B. Temporal arteritis in Israel. A review of 47 patients. J Rheumatol. 1979 May-Jun;6(3):330–335. [PubMed] [Google Scholar]
  11. Graham E., Holland A., Avery A., Russell R. W. Prognosis in giant-cell arteritis. Br Med J (Clin Res Ed) 1981 Jan 24;282(6260):269–271. doi: 10.1136/bmj.282.6260.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huston K. A., Hunder G. G., Lie J. T., Kennedy R. H., Elveback L. R. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978 Feb;88(2):162–167. doi: 10.7326/0003-4819-88-2-162. [DOI] [PubMed] [Google Scholar]
  13. Jones J. G., Hazleman B. L. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981 Feb;40(1):1–5. doi: 10.1136/ard.40.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kyle V., Hazleman B. L. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989 Aug;48(8):658–661. doi: 10.1136/ard.48.8.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Messer J., Reitman D., Sacks H. S., Smith H., Jr, Chalmers T. C. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med. 1983 Jul 7;309(1):21–24. doi: 10.1056/NEJM198307073090105. [DOI] [PubMed] [Google Scholar]
  16. Myles A. B. Polymyalgia rheumatica and giant cell arteritis: a seven-year survey. Rheumatol Rehabil. 1975 Nov;14(4):231–235. doi: 10.1093/rheumatology/14.4.231. [DOI] [PubMed] [Google Scholar]
  17. Spiera H., Davison S. Long-term follow-up of polymyalgia rheumatica. Mt Sinai J Med. 1978 Mar-Apr;45(2):225–229. [PubMed] [Google Scholar]
  18. Uriu S. A., Reinecke R. D. Temporal arteritis, steroid therapy, and pulmonary emboli. Arch Ophthalmol. 1973 Nov;90(5):355–357. doi: 10.1001/archopht.1973.01000050357003. [DOI] [PubMed] [Google Scholar]
  19. Wadman B., Werner I. Thromboembolic complications during corticosteroid treatment of temporal arteritis. Lancet. 1972 Apr 22;1(7756):907–907. doi: 10.1016/s0140-6736(72)90784-2. [DOI] [PubMed] [Google Scholar]
  20. von Knorring J. Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients. Acta Med Scand. 1979;205(5):429–435. doi: 10.1111/j.0954-6820.1979.tb06077.x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES